Orsus Therapeutics

The global cannabidiol (CBD) industry was worth £2.8 billion in 2020 and is expected to reach around £13.4 billion by 2028, with an annual growth rate of 21.2%. Orsus Therapeutics aims to invest in this thriving market by acquiring companies that offer excellent CBD-based wellbeing products. The majority of global demand for CBD comes from the health and wellness sectors. As governments relax regulations and more evidence emerges about the benefits of CBD, the demand is expected to continue growing. This makes CBD a promising and sustainable investment opportunity. CBD is a non-psychoactive compound found in the cannabis plant. It has properties that can reduce inflammation, relieve pain, soothe skin, and promote relaxation, making it a more natural choice for many consumers. Unlike THC, CBD does not cause a "high". Studies have shown a range of potential benefits, such as improving skin and pet care, aiding sleep, reducing anxiety, and relieving muscle pain. In 2018, the World Health Organization (WHO) published a report stating that CBD likely has health benefits and a good safety profile. CBD is legally sold as supplements and beauty products in various countries, including the UK, US, and parts of Europe. In response to customer demand, several well-known health and beauty retailers have begun stocking CBD products that can be purchased without a prescription. CBD oils, lotions, and edibles are becoming increasingly popular. The leadership team at Orsus, consisting of Dr. Adi Zullof Shani, Dwight Mighty, and Harry Chathli, focuses on CBD from an investor's perspective. They prioritize projects and companies that are sustainable, offer high-quality products, and comply with UK regulations. Together, Adi, Dwight, and Harry bring extensive experience in operations, capital markets, mergers and acquisitions, scientific research and development, academia, and industry.